ENTRY       D10754            Mixture   Drug
NAME        Lamivudine and raltegravir;
            Lamivudine and raltegravir potassium;
            Dutrebis (TN)
COMPONENT   Lamivudine [DR:D00353], (Raltegravir potassium [DR:D07133] | Raltegravir [DR:D06676])
CLASS       Antiviral
             DG03107  Anti-HIV agent
REMARK      ATC code: J05AR16
EFFICACY    Antiviral
COMMENT     Treatment of HIV infection
TARGET      HIV-1 reverse transcriptase [KO:K24802]
            HIV-1 integrase [KO:K24803]
  PATHWAY   ko03230(K24802+K24803)  Viral genome structure
            ko03240(K24802+K24803)  Viral replication
            ko03250(K24802+K24803)  Viral life cycle - HIV-1
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AR Antivirals for treatment of HIV infections, combinations
                 J05AR16 Lamivudine and raltegravir
                  D10754  Lamivudine and raltegravir
            Drug groups [BR:br08330]
             Antiviral
              DG03107  Anti-HIV agent
               D10754  Lamivudine and raltegravir
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HIV integrase inhibitor
                D10754  Lamivudine and raltegravir
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10754
DBLINKS     PubChem: 273220350
///
